A Double-Blind Randomized Phase I Clinical Trial Targeting ALVAC-HIV Vaccine to Human Dendritic Cells by Eller, Michael A. et al.
A Double-Blind Randomized Phase I Clinical Trial
Targeting ALVAC-HIV Vaccine to Human Dendritic Cells
Michael A. Eller
1., Bonnie M. Slike
1., Josephine H. Cox
2, Emil Lesho
3, Zhining Wang
1, Jeffrey R. Currier
1,
Janice M. Darden
1¤, Victoria R. Polonis
1, Maryanne T. Vahey
3, Sheila Peel
1, Merlin L. Robb
1, Nelson L.
Michael
1, Mary A. Marovich
1*
1U.S. Military HIV Research Program (MHRP), Rockville, Maryland, United States of America, 2International AIDS Vaccine Initiative (IAVI), New York, New York, United
States of America, 3Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America
Abstract
Background: We conducted a novel pilot study comparing different delivery routes of ALVAC-HIV (vCP205), a canarypox
vaccine containing HIV gene inserts: env, gag and pol. We explored the concept that direct ex vivo targeting of human
dendritic cells (DC) would enhance the immune response compared to either conventional intramuscular or intradermal
injections of the vaccine alone.
Methodology/Principal Findings: Healthy HIV-1 uninfected volunteers were administered ALVAC-HIV or placebo by
intramuscular injection (IM), intradermal injection (ID) or subcutaneous injection (SQ) of autologous ex vivo transfected DC
at months 0, 1, 3 and 6. All vaccine delivery routes were well tolerated. Binding antibodies were observed to both the
ALVAC vector and HIV-1 gp160 proteins. Modest cellular responses were observed in 2/7 individuals in the DC arm and 1/8
in the IM arm as determined by IFN-c ELISPOT. Proliferative responses were most frequent in the DC arm where 4/7
individuals had measurable responses to multiple HIV-1 antigens. Loading DC after maturation resulted in lower gene
expression, but overall better responses to both HIV-1 and control antigens, and were associated with better IL-2, TNF-a and
IFN-c production.
Conclusions/Significance: ALVAC-HIV delivered IM, ID or SQ with autologous ex vivo transfected DC proved to be safe. The
DC arm was most immunogenic. Proliferative immune responses were readily detected with only modest cytotoxic CD8 T
cell responses. Loading mature DC with the live viral vaccine induced stronger immune responses than loading immature
DC, despite increased transgene expression with the latter approach. Volunteers who received the autologous vaccine
loaded mature DC developed a broader and durable immune response compared to those vaccinated by conventional
routes.
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Introduction
The HIV pandemic remains largely unchecked with massive
morbidity, mortality and social instability consequences. Current
estimates indicate about 60 million people have been infected
worldwide, with Africa incurring the greatest number (70%) of
global infections [1]. It is increasingly apparent that controlling
this disease will require unprecedented measures from the
scientific field, especially with regards to the development of an
efficacious vaccine [2]. To date, nearly 200 clinical trials have
been conducted with potential vaccine candidates to prevent or
treat HIV infection; one-quarter of these trials explored the use of
pox-based viral vectors [3]. ALVAC, a host range restricted
canarypox virus, is replication incompetent in humans and
considered safe. Recently, ALVAC has shown modest efficacy in
preventing HIV acquisition in the ALVAC-HIV/AIDSVAX B/E
Phase III trial conducted in Thailand (RV144) [4]. Despite the
encouraging outcome, immune responses with ALVAC need
further understanding and optimization.
A relatively novel vaccine strategy incorporates reinfusion of
autologous vaccine loaded dendritic cells (DC). Since their
discovery in 1973, a growing body of literature identifies the
central role of DC in antigen processing, presentation and
establishing protection from pathogens through primary immunity
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24254[5,6]. DC are required for the induction of antigen specific
immune responses including cell proliferation and functional
maturation of specific T cell clones [6,7].
Based on pioneering work in animals and humans [8,9,10],
promising studies in late stage cancer patients [11,12,13], and our
own pre-clinical activities [14], we completed a pilot study in
healthy, low-risk, HIV uninfected volunteers to compare direct ex
vivo targeting of DC with standard immunization routes. We
reasoned that DC vaccination would enhance the immune response
and improve our understanding of optimal immunization. We used
monocyte derived DC to generate large numbers of cells for
vaccination similar to those used in other DC vaccination protocols
[15].Monocyteswererecentlyshowntofullydifferentiatein vivo into
potent antigen presenting DC-SIGN expressing DC that localize to
the lymph nodes after appropriate stimulation [16].
We selected an experimental canarypox vaccine previously
tested in adults and children, vCP205, containing HIV-1 env, gag
and pol genes. This particular study design was novel as autologous
DC vaccination had been limited to therapeutic studies, and not
yet used in healthy donors for a preventative vaccine. Our results
show that multiple autologous ex vivo loaded mature DC
vaccinations were well tolerated and more immunogenic than
conventional vaccine delivery routes.
Materials and Methods
Objectives
The study objectives were to assess the safety, tolerability and
immunogenicity of ALVAC-HIV administered subcutaneously via
exvivo transfected autologousDC,intradermally,orintramuscularly.
Ethics statement and regulatory approval
The clinical protocol was entitled ‘‘A Phase I Study of Aventis
Pasteur Live Recombinant ALVAC-HIV (vCP205, HIV-1 env/
gag/pol) in Seronegative Adults Administered (1) SQ via ex vivo
Transfected Autologous Dendritic Cells, (2) Intradermally, or (3)
Intramuscularly’’. This protocol, designated RV138 by nominal
convention within our program, was sponsored by the Office of
the Surgeon General and approved by the Institutional Review
Board of the Division of Human Subjects Protection, Walter Reed
Army Institute of Research. This study was conducted under the
auspices of the US FDA, IND #BB12207, and registered with the
NIH clinical trials.gov as NCT#00013572. All volunteers
provided written informed consent following discussion and
counseling by the clinical study team prior to enrollment and
before any study related procedures were performed.
Study design
Eligible participants were randomized to one of three delivery
routes: Arm 1: SQ via ex vivo loading of autologous DC, Arm 2:
direct ID injection or Arm 3: direct IM injection. We used a rolling
enrollment process and allowed replacements of volunteers while
the study was open to reach a target total n=36 individuals, 12 per
group. Within each group, volunteers were further randomized to
receive either vCP205 vaccine or placebo at a 2:1 ratio.
Vaccinations were given at 0, 1, 3 and 6 months. All subjects
underwent leukapheresis pre-vaccination and 2 weeks post-
vaccination. Other routine blood draws were performed per
protocol throughout the study. All volunteers were observed for
one hour post-vaccination, contacted by telephone within 48 hours
post-vaccination and returned to the clinic for a 2-week post-
vaccination safety visit. Routine safety visits included solicitation of
adverse events in the interval since their last visit, review of a 7-day
diary card, directed physical exam and routine safety labs. The trial
protocol and CONSORT checklist can be found in the supporting
information; see Checklist S1 and Protocol S1.
Participants and setting
RV138 was conducted in Rockville, MD within the Military
HIV Research Program where all samples and data were
collected. Eligible volunteers were healthy, aged 18–55 years,
HIV uninfected and low risk for acquisition of HIV infection (e.g.
no intravenous drug use, no known sexual exposure to HIV+
partner). Female participants agreed to avoid pregnancy for the
duration of the study and a negative serum pregnancy test was
required prior to each vaccination. Full details of inclusion and
exclusion criteria may be found in the protocol (Protocol S1).
Interventions
ALVAC-HIV (vCP205, Aventis Pasteur, France) is a recombi-
nant canarypox virus expressing HIV-1 env, gag and pro subtype B
gene products. The vCP205 env is comprised of a gp120 MN + a
TM gp41 LAI. The HIV genes are inserted into the C3 locus and
are regulated by the vaccinia virus H6 and I3L promoters. The
lyophilized vCP205 vaccine (10
6.5 TCID50/vial) was reconstituted
to 1 ml and administered at the following doses: 1.0 ml IM into
deltoid, 0.5 ml ID given by 460.125 ml injections into the volar
aspect of forearm, and approximately 3–6610
6 DC were injected
in the superficial subcutaneous aspect of the inner arm within
10 cm of the axilla. For Groups II and III, saline was administered
as the placebo control. For the DC arm (Group I), those receiving
placebo were administered autologous DC pulsed with KLH
(injection 1) or no antigen (subsequent injections).
Outcomes
The primary endpoints were the evaluation of safety and
tolerability as well as immunogenicity. All subjects were observed
in the clinic for local and systemic reactions post vaccination and
instructed to report any reactions occurring over the next 7 days.
Routine safety labs were performed 14 days after each vaccination,
along with a physical examination. Primary measures of
immunogenicity included lymphocyte proliferation, CTL respons-
es and IFN-c production in response to vaccine component
antigens. Ancillary immunogenicity measures included assessment
of the breadth of humoral responses to vaccine component
antigens, mapping of cross-reactive cellular epitopes and analysis
of the cytokine profile produced during lymphocyte proliferation.
Sample Size
This study was intended as an exploratory proof-of-concept to
test the safety of two new routes of vaccine delivery via dendritic
cells and intradermal injection. A sample size of 12 volunteers per
group (8 active product and 4 placebo) provided approximately
70% power to detect a true difference, should one exist, in CTL
response between the DC arm and the better of the IM and ID
arms. All subjects receiving at least one injection of vaccine were
included in the safety and tolerability analyses.
Randomization and blinding
Subjects who met initial admission criteria were assigned
personal identification numbers and screening numbers at the
first screening visit. After a volunteer was deemed eligible, the
screening number became the study ID number. All three arms
were enrolled concurrently and subjects were randomly assigned
to an arm. Within each arm subjects were randomly assigned to
active vaccine or placebo according to a list generated by the
MHRP Data Coordinating and Analysis Center. Study site staff
ALVAC-HIV Vaccine Targeting DC
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placebo or vaccine, but not to study arm.
Cells
Peripheral blood mononuclear cells (PBMC) were isolated from
apheresis products obtained at visits 1 (v.1) and 11 (v.11), or from
whole blood drawn at alternate visits. Apheresis product or whole
blood was diluted with PBS, layered over Ficoll-Paque Plus (GE
Healthcare, Piscataway NJ), centrifuged and harvested as
previously described [14]. The apheresis products were washed
more extensively than whole blood derived PBMC with large
volumes of PBS to remove platelets. Cells were cryopreserved in
10% dimethyl sulfoxide (Sigma, St. Louis MO), 12.5% human
serum albumin (SeraCare Life Sciences, West Bridgewater MA),
X-VIVO-15 media (BioWhittaker/Lonza, Walkersville MD) and
maintained in vapor phase liquid nitrogen storage until use.
Generation of clinical-grade DC
Autologous clinical-grade DC were generated as described
[14,17]. Briefly, monocytes isolated by adherence to tissue culture
dishes were incubated for 6 days in RPMI-1640, 1% autologous
heat inactivated human plasma, 2 mM L-glutamine (BioWhit-
taker/Lonza) and 20 mg/ml gentamicin (American Pharmaceu-
tical Partners, Los Angeles CA) supplemented with the recombi-
nant cytokines IL-4 (800 U/ml; CellGenix, Antioch IL) and
granulocyte-macrophage colony-stimulating factor (GM-CSF,
1000 U/ml; McKessen, Richmond VA). To generate mature
DC, 20% vol/vol autologous monocyte conditioned media
(MCM) was added on day 6 and cells were harvested on day 7
[14]. DC phenotype and maturation was assessed by flow
cytometry using phycoerythrin (PE)-conjugated monoclonal anti-
bodies to CD1a, CD3, CD14, CD20, CD25, CD80, CD86 and
HLA-DR (BD Biosciences, San Jose CA) and CD40 and CD83
(Beckman Coulter, Fullerton CA). The pre-specified release
criteria included maturation (mDC $50% CD86
+ and/or
CD83
+), .70% viability, with a negative sterility panel including
gram stain, aerobic and anaerobic cultures, mycoplasma culture
and PCR, and endotoxin (Limulus amoebocyte lysate assay).
Ex vivo loading of DC with vaccine
DC vaccinations were prepared fresh for every injection. For
the first 14 vaccinations in 4 donors, immature DC were first
matured overnight with MCM and then loaded with vaccine the
following morning. However, the loading sequence was modified
during the trial in order to increase intracellular p24 expression, as
an estimate of vaccine-loading efficiency. For all subsequent
vaccinations, the DC were first loaded with vaccine in the
immature state, followed by overnight MCM maturation prior to
injection. For the first vaccination in all donors, their DC were
exposed to keyhole limpet hemocyanin (KLH, Calbiochem/EMD,
Gibbstown NJ or Biosyn, Lewisville TX)) as a control for immune
response to a neoantigen and DC integrity. The maximum
number of available DC, up to 6610
6, were injected at each
vaccination.
Measurement of serum IgG titers by ELISA
The following antigens were coated overnight at 4uC onto
Immulon-2 microtiter plates (Fisher Scientific, Pittsburgh, PA):
p24 (0.5 mg/ml, ImmunoDiagnostics, Inc.); gp160-MN/LAI
(0.5 mg/ml, PMC, France); and ALVAC CPpp (4 mg/ml, Aventis
Pasteur, France). The p24 and gp160-MN/LAI were coated in
PBS, pH 7.4 containing 0.01% thimerosal. The ALVAC CPpp
was coated onto plates in bicarbonate buffer (dH2O, sodium
carbonate monohydrate, sodium bicarbonate, pH 9.6). Plates were
blocked with serum diluent for 1 hour prior to serum addition
then washed with buffer (PBS with 0.1% Tween 20, pH 7.4).
Serum (100 ml in two-fold dilutions in wash buffer with 5% skim
milk, pH 7.4) was added for 1 hour at 37uC. After incubation with
the sera, plates were washed and 100 mL of horseradish
peroxidase-conjugated goat anti-human IgG was added (Kirk-
gaard & Perry, Gaithersburg MD) to each well for 1 hour at 37uC.
Plates were washed, TMB substrate (Kirkgaard & Perry) was
added for 15 min and the reaction was stopped with 1 M
phosphoric acid. The optical density for each well was read at a
wavelength of 410 nM on a VersaMax reader (Molecular Devices,
Inc., Gaithersburg MD).
Cytotoxic T lymphocyte (CTL) assay
A standard chromium release CTL assay was performed on
freshly isolated PBMC with in 6 hours of collection as previously
described [18]. In vitro stimulations were set up using 20610
6
freshly isolated PBMC, of which 20% (stimulators) were infected
with a vaccinia recombinant expressing HIV subtype B env gp120
MN gene and B gag/pol IIIB genes (vP1291) for 1462 days.
Autologous EBV-transformed B cells (TBC) were infected
overnight with vaccinia recombinants (Virogenetics, Troy NY)
expressing subtype B (MN) env (vP1174) and subtype B (IIIB) gag/
pol (vP1287), or empty vector (vP1170), and labeled with
51Cr for
use as targets in the CTL assay. Cold target empty vector infected
TBC were used to compete and absorb background vaccinia
responses. CTL assays were performed at effector to target (E:T)
ratios of 50:1 and 25:1, with whole, CD8- or CD4-depleted PBMC
in order to verify CD8 restriction. Specific lysis was calculated as
[(experimental release-spontaneous release)/(maximum release-
spontaneous release)]6100. Background vaccinia responses were
subtracted from HIV-1 specific responses. A positive CTL is
defined as specific lysis greater than 10% at either E:T ratio,
provided that elevated lysis at 25:1 is supported by lysis at 50:1.
The response was CD8
+ T cell mediated if depletion of CD8
+ T
cells removed 50% of the HIV antigen specific lytic activity, while
removal of CD4
+ cells maintain at least 5% HIV specific lysis.
IFN-c ELISPOT assay
The ELISPOT assay, as described previously [18], was
performed at visit 1 and 9 additional visits throughout the trial.
Fresh PBMC (1–2610
5) were added in duplicate wells, or for the
PBMConlywells inquadruplicate. Poolsof peptides matched to the
vaccine strain (see below) or controls were added at a final
concentration of 2 mg/ml. Determination of CD8
+ T cell
dependence was achieved by immunomagnetic bead depletion
(Dynal, Upsalla,NY).The ELISPOT plates wereexamined under a
stereomicroscope and spots were evaluated with an Automated
Elispot Reader System with KS 4.3 software (Carl Zeiss, Thorn-
wood, NY). The results are expressed as the number of IFN-c
secreting cells or spot forming cells (SFC) per million PBMC. A
positive response was defined as .46background and .55 SFC/
10‘6 PBMC, based on the Merck Laboratory definition [19].
Synthetic HIV peptides and other reagents
Peptides were obtained from the NIH AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID, NIH.
Peptides (15mers overlapping by 11, with a minimum purity of
,80%) were pooled for use in the ELISPOT assay; 212 env
(catalog #6451) and 122 Gag (catalog #5107) peptides were made
into 9 and 5 pools of 25 peptides, respectively. A pool of 23
peptides synthesized in-house using Fmoc chemistry and standard
solid-phase techniques (Excel automated synthesizer; Waters,
ALVAC-HIV Vaccine Targeting DC
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and Flu (CEF pool, [20]) was used as a positive control.
Lymphocyte proliferation assay (LPA)
PBMC were plated at 1.5610
5 cells/well in 96-well plates in
media alone or with antigen in triplicate wells and incubated for 6
days at 37uC, 5% CO2. Antigens included aldrithiol-2 inactivated
HIV-1 MN (AT-2 HIV, 100 ng capsid antigen/ml, lot #3763
courtesy J. Lifson, AIDS and Cancer Virus Program, SAIC-
Frederick, Inc., NCI Frederick, Frederick MD); KLH, 100 mg/ml;
HIV-1 gp160 (10 mg/ml) and HIV-1 p24 (12.5 mg/ml), both from
Advanced BioScience Laboratories, (Kensington, MD). Microvesi-
cles (MV, Jeff Lifson, NCI) from uninfected cultures were used at an
equivalent protein concentration as a negative control for AT-2
HIV, and phytohemagglutinin (1 mg/ml, Sigma, St.Louis, MO) was
used as a positive control. The cells were pulsed with 1 mCi/well
[
3H]thymidine and harvested onto filter mats for scintillation
counting on day 6. Small volumes of cell free supernatants were
pooled from replicate wellsat specifiedintervalsforcytokineanalysis.
Fluorescent labeling of PBMC
Thawed PBMC were labeled with carboxy-fluorescein dicetate
succinimidyl ester (CFDA-SE) according to manufacturer’s
instructions (Invitrogen, Carlsbad CA). Briefly, cells were labeled
with 2.5 mM CFDA-SE in PBS supplemented with 5% fetal calf
serum at 37uC. To quench the reaction, cells were washed in cold
5% FCS/PBS and washed twice with proliferation media. Cells
were plated at 2610
6 cells/well in 48-well plates in media alone or
with antigens as used in the LPA. Following a 6-day incubation
cells were harvested and stained for surface marker expression
using monoclonal antibodies against CD3 (PE conjugate), CD4
(allophycocyanin (APC) conjugate) and CD8 (peridinin chloro-
phyll protein (PerCP) conjugate) (BD Biosciences).
Quantitation of cytokines
Supernatants from LPAs at days 2 and 6 were quantified using
human cytometric bead array kits (BD Biosciences) per manufac-
turer’s protocol. Cocktails of capture beads for IL-1b, IL-2, IL-4,
IL-6, IL-10, IL-12, INF-c, or TNFa were added to a 96-well filter-
plate (Millipore) with 50 mL supernatant. After 1 h, 50 mLP E
detection reagent was added to each well and the plate was
incubated for 2 hours. Samples were washed and resuspended in
150 mL wash buffer, collected on an LSR-II flow cytometer and
analyzed with FCAP Array software (BD Biosciences).
Gene regulation assessment
Total RNA was extracted from PBMC stimulated with either
AT-2 HIV or control MV, assessed for quality and quantity and
prepared for hybridization to the Affymetrix Human Genome
Focus Genechip essentially as described previously [21]. Data were
normalized using Robust Multichip Averaging. All nonexpresseed
genes were eliminated from further analysis. Differentially
expressed genes were identified using Significance Analysis of
Microarrays (SAM) v1.21 and the Database for Annotation,
Visualization and Integrated Discovery.
Statistical analysis
All assays used preset criteria for positivity. For CTL and
ELISPOT assays, the following criteria were also applied 1) the
presence of repeat responses over multiple time points; more than
one positive response post-vaccination and 2) data for individuals
where the baseline samples were positive were not included in the
analysis. Statistical analyses for CTL and ELISOPT were
performed independently by the Data Analysis and Coordinating
Center at MHRP. Additional statistical analyses were performed
using Prism (GraphPad Software, LaJolla CA).
Results
Enrollment, participant flow and demographics
Forty-nine healthy HIV seronegative volunteers were random-
ized to the three study arms: (1) autologous pulsed DC (n=24), (2)
ID injection (n=13) or (3) IM injection (n=12) (Consort diagram,
Fig. 1a). Two weeks prior to the first vaccination (v.1), all subjects
underwent apheresis to obtain PBMC for the generation of
autologous DC (DC arm only) and for baseline in vitro
immunologic measurements (all arms) (Fig.1b). We were unable
to generate DC from 5 of the volunteers due to a technical issue
with a manufactured reagent. One volunteer became pregnant
prior to vaccination, a second was excluded due to prior receipt of
an HIV vaccine and a total of 7 exited the study prior to
vaccination. The last donor randomized to the DC arm was later
excluded after enrollment closed and was not replaced, This
resulted in only 11 total volunteers in this arm. All 35 volunteers
who completed their vaccination series (ID, IM or DC) were
included in the immune analysis. The median age of subjects was
42.2 years with an even distribution of males and females in each
group. As previously reported [22], our study demographics reflect
the greater Washington, DC region, see Table 1. Vaccinations
were given at 0, 1, 3 and 6 months. A post-vaccination apheresis
was performed 2 weeks after the final vaccination (v.11) for
presumed ‘‘peak immunogenicity’’.
Safety and tolerability
All vaccinations and delivery routes were well tolerated. After
each vaccination, volunteers were observed in the clinic for
60 minutes for signs of local or systemic reactions. They were
educated on how to use a diary card to record their symptoms for
the week after vaccination. Diary cards were reviewed and
volunteers were assessed for symptoms at the subsequent safety
visit. The post vaccination reactions were mild, transient, mainly
local and typically included erythema, induration (Fig. 2),
tenderness or warmth (data not shown). The highest frequency
of local reactions was in the ID group, with fewer in the DC group
and very few in the IM group. Some subjects reported mild
systemic events including headache or transient myalgia, but most
events did not require analgesics, nor did they interfere with the
subjects’ daily routine. No severe adverse events occurred.
Humoral responses
Antibody responses to the ALVAC vector and the HIV proteins
env gp160 and gag p24 were monitored throughout the study by
ELISA. Geometric mean binding antibody titers (GMT) detected
over a two-year period for all tested antigens are shown (Fig. 3). As
expected, after the final vaccination, the canarypox vector elicited
strong responses (v.11, .10,000 GMT) in all groups. This
response tapered off yet remained positive (v.16, .200 GMT)
for 18 months post vaccination. The gp160 responses were highest
in the IM route and comparable in the ID and DC routes. All
gp160 responses decreased over time and reverted to negative 18
months after vaccination (v.16, ,100 GMT). The ELISA gag
responses were lowest in magnitude and especially notable for
their absence in the DC arm.
CTL and ELISPOT responses
IFN-c ELISPOT responses were assessed from fresh PBMC
processed within 4 hours of blood draw using vaccine-matched
ALVAC-HIV Vaccine Targeting DC
PLoS ONE | www.plosone.org 4 September 2011 | Volume 6 | Issue 9 | e24254Figure 1. Study Design. (A) Consort diagram. (B) Study timeline. Vaccinations were administered at 0, 1, 3 and 6 months. All study subjects
underwent apheresis prior to initial vaccination (visit 1) and 2 weeks following the final vaccination (visit 11).
doi:10.1371/journal.pone.0024254.g001
Table 1. Demographics of study volunteers.
Study Arm N Median Age Male:Female Racial Demographics
Ratio African Amer. Caucasian Hispanic Asian Other
DC 11 42.3 6:5 36% 55% 9% 0% 0%
ID 12 41.6 6:6 42% 50% 0% 8% 0%
IM 12 41.8 5:7 33% 58% 0% 0% 8%
Total 35 42.2 17:18 37% 54% 3% 3% 3%
doi:10.1371/journal.pone.0024254.t001
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IFN-c ELISPOT responses and 1/8 individuals in the IM arm had
HIV-env IFN-c ELISPOT responses. In these individuals, the
responses were seen at more than one time point post vaccination,
were of modest magnitude and were CD8 restricted as defined by
magnetic bead depletion studies. HIV-env CD8 specific CTL
responses as measured by
51Cr release were detected in 2/8
individuals in the IM arm (Table 2). Since one of the IM
participants had responses detected over multiple time points by
ELISPOT, CTL and whole blood intracellular cytokine staining
(ICS, data not shown), we further explored this individual’s
immune response at v.16, collected 18 months after the last
vaccination. At this visit, fresh CTL lysis was 70% and 50% at E:T
of 50:1 and 25:1 respectively, and confirmed to be CD8 T cell
dependent. The in vitro CTL culture was maintained and
expanded using IL-2 and autologous B cells expressing MN Env.
A matrix ELISPOT with the in vitro expanded PBMC was
performed and an Env epitope CTRPNYNKRKRIHIG (B0703)
was mapped in this individual with frequencies of 484 and 979
SFC/10,000 PBMC. The in vitro expanded PBMC were
phenotyped in an ICS and further tested for CTL recognition of
Env CTRPNYNKRKRIHIG peptide and vaccinia MN pulsed B
cell targets. The phenotype of the cells was confirmed to be CD8
positive (41.5% CD3
+/CD8
+) and these cells mediated 70% killing
of peptide and vaccinia MN pulsed B cell targets at an E:T ratio of
20:1 as shown in Figure S1.
HIV specific lymphoproliferative responses
Pre- and post-vaccination PBMC were assayed for HIV specific
responses in the LPA (Fig. 4A). In the DC arm, 4/7 vaccinees
responded to at least one of the HIV antigens tested, with 3/7
responding to all three antigens tested. Responses in the IM group
were seen to AT-2 HIV and p24, but not to gp160. The ID arm
showed the most limited responses: 2/8 total responders, both
responsive to p24, one responsive to gp160, and none to AT-2
HIV. We further examined whether the responses seen at 2-weeks
post-vaccination were durable. PBMC from all four DC arm
responders, isolated from apheresis or whole blood draws over the
time period covering pre-vaccination up to 18 months post-
vaccination, were tested. After the third vaccination, cells
remained strongly responsive to the antigens, but not the negative
control, with at least 18-month durability after the final
vaccination (Fig. 4B).
Identification of proliferating cell populations
Along with the traditional
3H-thymidine incorporation LPA
assay, cells were subjected to identical antigen stimulation
conditions in a flow cytometry-based proliferation assay. PBMC
were labeled with CFDA-SE prior to stimulation with antigen. Co-
labeling with monoclonal antibodies to CD3, CD4 and CD8
allowed for the identification of dividing T cell populations.
Figure 4E shows overlays of pre-vaccination and post-vaccination
CD4
+ and CD8
+ populations of two representative DC arm
Figure 2. Post-vaccination reactogenicity. Post injection-site reactogenicity symptoms including induration (left panel) and erythema (right
panel) after each vaccination for all study groups (autologous DC (DC), intradermal (ID) and intramuscular (IM) routes).
doi:10.1371/journal.pone.0024254.g002
Figure 3. Antibodies develop after vaccination. Humoral responses to the vaccine vector (ALVAC, left panel) and insert genes HIV-gp160
(middle panel) and HIV-p24 (right panel). Data points are the geometric mean titers (GMT)+SEM bars for all subjects within each study arm receiving
vaccine. Visit numbers are indicated and an asterisk (*) denotes vaccination visits. Closed diamonds, autologous DC route; open circles, ID route; open
squares, IM route.
doi:10.1371/journal.pone.0024254.g003
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population, there is evidence of proliferation within the CD8 T cell
compartment in response to both AT-2 HIV (left panels) and to
p24 (right panels).
Effect of antigen loading sequence in the DC arm
Pre-clinical experiments suggested that maturing the DC before
loading them with vaccine yielded a population of cells that were
fully mature and expressing p24 [14]. Midway through the study,
we compiled the mean p24 expression in the injected DC
populations and found it was below the predetermined minimum
of 5% expression. To improve p24 expression, the loading sequence
was inverted so that immature DC were loaded with vaccine and
subsequently matured. Figure 5A shows the distribution of DC
vaccine injections based on loading sequence. Three patients
Figure 4. HIV specific lymphocyte proliferation responses. LPA responses of PBMC from (A) pre-vaccination (v.1, white bars) and two weeks
post final vaccination (v.11, black bars) from all vaccinees. Responses to whole inactivated HIV (AT-2 HIV), HIV-gp160 and HIV-p24 were measured and
reported as a lymphocyte stimulation index (LSI, antigen response/unstimulated control). An LSI of .5 (dashed line) is considered positive. (B)
Durability of proliferative responses up to 18 months post final vaccination for the 4 responders in the DC vaccination arm. Responses to HIV
antigens, keyhole limpet hemocyanin (KLH, positive control for DC injection) and aldrithiol-2 microvessicles (MV, negative control for AT-2 HIV) are
expressed as mean LSI6SEM from LPAs performed on fresh PBMC. (C) Proliferative responses pre-vaccination (grey histograms) and 2 weeks post
final vaccination (black lines) to HIV antigens were measured by flow cytometry using CFDA-SE. CD4
+ and CD8
+ T cell responses are shown for two
donors from the DC arm stimulated with either AT-2 HIV (left panels) or HIV-p24 (right panels). Proliferative response is measured as the percent of
cells that have undergone division and show reduced intensity of CFSE. The ratio of proliferative response post-vaccination to pre-vaccination is
shown.
doi:10.1371/journal.pone.0024254.g004
Table 2. CTL and IFN-c ELISPOT responses to any HIV
antigen.
IFN-c ELISPOT CTL
Arm Placebo Vaccine Placebo Vaccine
ID 0/4 0/8 0/4 0/8
DC 0/4 2/7
a 0/4 0/7
IM 0/4 1/8
b 0/4 2/8
Total # responders 0/12 3/23 0/12 2/23
Positive control responses 12/12
c 23/23
c na na
agag responses,
benv responses,
cPHA responses.
doi:10.1371/journal.pone.0024254.t002
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immature-loaded DC, and two received a combination. DC
vaccinations were characterized and compared based on loading
sequence for p24 (loading efficiency), CD83 expression (maturation
level), viability and number DC per injection (Fig. 5B). Overall, the
immature-loaded DC expressed statistically higher levels of p24 (2-
fold more) than the mature-loaded cells. Following maturation of
the immature-loaded cells, significant decreases were seen in
expression of CD83 and cell viability. Decreased viability, along
with other technical issues in recovery of the immature-loaded DC,
lead to fewer total DC available for injection (6 M vs. $3 M). The
decreaseinresponsesinthe DCarmvaccineestothe control protein
KLH, as well as AT-2 HIV, coincided with the change in DC
loading sequence (Fig. 5C).
Cytokine production
We measured cytokines in the LPA supernatants at days 2 and 6
using human cytometric bead array assays for IL-1b, IL-2, IL-4,
Figure 5. DC vaccine characterization. (A) Schematic representation of the DC maturation sequence. Autologous DC were loaded with vaccine
either after maturation (black bars) or before maturation (grey bars). (B) Characteristics of vaccine-loaded DC, segregated by loading/maturation
sequence. Expression of HIV-p24 and the maturation marker CD83 were assessed by flow cytometry. The number of DC per injection and cell viability
at the time of injection were assessed by visual counts using Trypan Blue exclusion. P-values represent the statistical difference as determined by an
unpaired t-test. (C) Proliferative responses of DC arm vaccinees to KLH (white bars) and AT-2 HIV (black bars). Data is shown as mean LSI6SEM from
LPAs performed on fresh PBMC isolated between visits 1–16. (D) Cytokine secretion following AT-2 HIV stimulation of PBMC collected pre-vaccination
(v.1, white bars) and two weeks following the final vaccination (v.11, black bars). IFN-c, TNF-a, IL-2 and IL-10 secretion from representative responder
and non-responder vaccinees from the DC arm are shown.
doi:10.1371/journal.pone.0024254.g005
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TNF-a, IL-2 and IL-10 production at pre- and post-vaccination
time points (v.1 and v.11, respectively, Fig. 5D) because they are
commonly monitored in vaccine studies (IFN-c, TNF-a and IL-2)
and relevant with regard to ‘‘tolerance’’ or ‘‘ignorance’’ in the case
of IL-10. Representative data from DC arm responder and non-
responder subsets are shown. Early IL-2 and TNF-a were detected
followed by late IFN-c in the responders, while minimal cytokine
production was observed in the non-responders. IL-10 was not
detected in any donor supernatants. Because prior reports
indicated that immature antigen-loaded DC could tolerize the
immune response [8], we conducted flow cytometric analysis of
pre- and post-vaccination PBMC from 10/11 of the DC vaccinees,
responders and non-responders, using FoxP3, CD27, CD25
staining. There were no increases in Treg cells observed in any
DC vaccine recipient throughout the study (data not shown).
Genomic analysis
Following in vitro stimulation with AT-2 HIV, RNA extracted
from pre- and post-vaccination PBMC from the 4 DC arm
responders was evaluated by gene array analysis for differential
gene expression. After stimulation with AT-2 HIV, but not with
control MV or media alone, distinct gene expression patterns
emerged between the pre-vaccination and post-vaccination
samples (Fig. 6A). The patterns were statistically significant and
resolvable in a stringent analysis using a false discovery rate of
,1%. Correlating with the proliferation and cytokine responses,
there was no differential expression seen in the pre-vaccination
cells, nor in any of the post-vaccination cells of the non-responder
subset. However, in the post-vaccination cells in the responder
subset, 2 genes were upregulated and 203 down regulated
(Table 3). The functional groups most affected during the
proliferation responses included those controlling apoptosis and
programmed cell death, response to virus, and regulation of NFkB
(Fig. 6B).
Discussion
Classical vaccination techniques, centered on the induction of
humoral and cellular immunity against HIV, have yielded
disappointing results. However, recent data from the Phase III,
RV144 Thai study using a similar canarypox viral vector
(vCP1521) and a protein subunit boost showed a modest (31%)
reduction in HIV acquistion despite minimal T cell responses as
detected by IFN-c ELISPOT [4]. This level of ELISPOT activity,
in the range of 15–40%, is fairly typical for ALVAC-HIV studies
[23,24,25]. Notably, most vaccinees in RV144 showed lympho-
proliferative responses, CD4 responses to HIV-env by ICS and
developed binding antibodies to vaccine components. The only
difference between the canarypox vector in this study (vCP205)
and the Thai trial (vCP1521) is in their respective env sequences:
here in RV138 we used an MN (subtype B) and in the RV144
Thai trial, 92TH023 (subtype A/E) was used. Immune correlates
of protection are under active investigation for the Thai study. In
this context, it is incumbent on researchers to explore new avenues
for vaccine development and broaden our understanding of the
assessment of immune responses to vaccination. To this end, we
conducted a randomized, controlled double-blinded HIV vaccine
trial comparing standard immunization routes to a novel delivery
route using autologous ex vivo loaded dendritic cells. This DC
targeted approach to vaccination is labor intensive and ultimately
non-deployable on a large scale, but can be informative for vaccine
development.
We found that all administration routes of vCP205, including
multiple rounds of autologous DC vaccination of healthy
volunteers, were safe and well tolerated. Similar to the RV144
Thai study, our study generated predominantly proliferative
responses in the CD4 T cell compartment. Qualitative differences
were detected in immune responses that were route dependent
with the ex vivo targeted DC being more immunogenic . IM . ID
as assessed in the functional LPA. Somewhat surprisingly, the ID
route, which targets a DC rich zone and is proposed to enhance
vaccine efficacy (22), induced the most limited of cellular
Figure 6. Antigen-specific differential gene expression. (A) Principal components analysis of differentially expressed genes for the group of
responders in the DC arm. Red spheres denote pre-vaccination state (Visit 1) and blue spheres denote post-vaccination status (Visit 11). The X-axis is
the first principal component, the Y-axis is the second principal component and the Z-axis is the third principal component. (B) Functional groups of
gene families most significantly down-regulated in response to in vitro AT-2 HIV stimulation of PMBC from the DC arm responders.
doi:10.1371/journal.pone.0024254.g006
Table 3. Differential gene expression after in vitro stimulation
with whole-inactivated HIV.
# of genes
up-regulated
# of genes
down-regulated
Stimulus NR
a R
b NR R
media alone 0 0 0 0
control microvesicles 0 0 0 0
AT-2 HIV 0 2
c 02 0 3
aNon-Responders,
bResponders,
coligophrenin-1 and neuropeptide ff receptor-1.
doi:10.1371/journal.pone.0024254.t003
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ID vaccine (50%) given the volume constraints of the dermal
compartment. We hypothesized that a reasonable dose-sparing
effect should be observable with half the dose. This pilot study
suggests there was no observed dose sparing effect giving the
vaccine intradermally.
There were clear responders and non-responders to DC
vaccination. In fact, the first 4 consecutive volunteers responded
to DC vaccination, whereas the last three did not. The presence or
absence of an HIV response coincided with the KLH responses
(Fig. 5C). Therefore, KLH served as an important control
neoantigen, indicating loss of DC integrity or compromise after
loading with a live viral vaccine since both active vaccinees and
placebo recipients’ DC were pulsed with KLH. It is important to
note that KLHspecific CD8T cellELISPOTresponseswerelowin
the DC arm (data not shown). The lymphoproliferative responses
elicited by DC vaccination were broad. Responses were detected to
whole inactivated HIV-1, as well as env (gp160) and gag (p24)
proteins. These responses were robust and durable; lasting up to 18
months post vaccination (Fig. 4B). In an effort to better characterize
the responding cells, we used the cell tracking dye CFDA-SE along
with phenotypic markers in a flow cytometric assay. While the
preponderance of dividing cells were CD4
+ T cells, there was
detectable proliferation in the CD8
+ compartment (Fig. 4C).
Despite proliferative activity in the CD8 T cell compartment,
cytolytic activity was low. This could be consistent with a recent
report that suggests that in the murine cancer setting, priming of a
CD8 immune response is indirectly mediated by DC [31].
A key difference between responders and non-responders was
their DC maturation status at the time of vaccine loading.
Maturing the DC first, then loading the vaccine, resulted in
greater immune responses despite significantly reduced p24
expression (Fig. 5B, left panel). It is possible that the mature
loaded DC were more functional and capable of priming immune
responses to the vaccine. When the DC were loaded with vaccine
in the immature state, though they expressed more p24, there was
reduced viability, decreased maturation (CD83 expression) and
technical difficulties which lowered the overall cell yield for
vaccination. In addition to our experience, independent reports
implicate a role for type I interferons in ALVAC loaded DC
showing that ALVAC exposed monocyte derived DC upregulate
the type I interferon signaling pathway and DC maturation status
influences downstream intracellular networks via a ‘‘molecular
switch’’ in IFNa/b signaling [32,33]. Taken together, integrating
our work and the existing literature, we suggest that mature DC
are better able to withstand viral vaccine loading and function as
primary inducers of immune responses. Our poxvirus data is
consistent with prior reports indicating immunologic benefit when
loading mature DC with either peptides or RNA [34,35].
As prior publications suggested that antigen loaded immature
DC were tolerogenic, we looked for, but did not find, either HIV
specific IL-10 production or the induction of Treg cells after
vaccination [36,37]. It is unclear whether DC non-responders were
unresponsive in an antigen specific manner or simply ignored the
signal having been insufficiently primed at the outset. The absence
of IL-10 (Fig. 5D) and stable circulating Treg phenotypes and
frequency pre- and post- vaccination (data not shown), are
reassuring observations, leaving open the idea that optimal DC
maturation and targeting could lead to more potent vaccines. Data
from our gene expression experiments also supports the idea that
cells from the non-responders were likely unresponsive, as opposed
to tolerized. This assay was designed as an adjunct to our functional
studies. We aimed to detect differences in gene regulation between
responders and non-responders when stimulated with HIV antigens
under LPA like conditions. The data show significant differences
between the two groups. In response to stimulation with AT-2 HIV,
post-vaccination cells from the responders showed differential
regulation of 205 genes. In contrast, no effect was seen in the
non-responder group, or in any of the pre-vaccination samples (data
not shown).
Cytolytic CD8 T cell response rates, particularly ELISPOTs
and chromium release CTLs, were low overall and similar to those
reported in previous canarypox studies [4,23,24]. One of the few
responders to generate a strong CD8 cytolytic response was
vaccinated by the IM route. This vaccinee responded to a peptide
sequence CTRPNYNKRKRIHIG, corresponding to position
296–301 (HXB2 numbering) in the V3 loop of the envelope
protein. This HLA-B0702 restricted peptide sequence appears to
be highly specific to MN subtypes and represents the first time
vaccine induced immune responses have been reported against
this epitope. While similar sequences denoted B7-R110 have been
reported in acute [26] and chronic [27,28,29] HIV-1 infection,
there is no known protection associate with this epitope [30].
Pilot studies are helpful in finding early safety signals, generating
hypotheses and driving innovation. Multiple doses of HIV-1
vaccine pulsed, ex vivo loaded autologous DC were safe and well
tolerated in normal healthy people and immunogenic in vivo. Study
limitations include the small study size, multiple arms and the
change in DC arm loading sequence that was not part of the
original study design. Additionally, we did not inject ALVAC SQ
as a comparator to the ex vivo ALVAC loaded DC injected
subcutaneously. Subset analysis of the DC responders and non-
responders were included for information purposes but cannot be
considered highly robust datasets. Yet, antigen specific prolifera-
tive immune responses were observed in both CD4
+ and CD8
+ T
cell compartments after DC vaccination and were associated with
IL-2, TNF-a and IFN-c production. Though a few DC vaccinees
did not respond to the vaccination series, no evidence for Treg cell
induction or tolerance was found. Non-responders and responders
were readily differentiated using expression profile analysis
supporting our results, but given the small sample size, further
study is needed. Targeting mature DC with viral vectors may
render cellular vaccines more functional and immunogenic.
Supporting Information
Figure S1 Characterization of T cell responses for
volunteer RV138.08 (IM group). Epitope mapping using a
peptide matrix ELISPOT assay with in vitro expanded (pIVS)
PBMC revealed that peptides 75 and 76 were positive. The main
epitope recognized was confirmed to be MN Env peptide #76
(CTRPNYNKRKRIHIG Env 296–310, HXB2 location). In an
ICS assay, 41.5% and 0.61% of the CD3/CD8 positive T cells in
the pIVS preparation were positive for IFN-c staining to p76
pulsed v.s. unpulsed autologous TBC (data not shown). The B cell
line was HLA typed and the class I HLA type of this individual is:
A*02011, A*74(01,02), B*0703, B*4001, Cw*0304s, Cw*0802s.
As predicted, the Env #75/76 peptide overlap contains a motif
matching the binding capacity of HLA-B*0703 with the minimal
epitope predicted to be RPNYNKRKRI. Peptide 76 was used to
continue in vitro stimulation of the culture and further
characterized in 51Cr-release CTL and ICS assays. (A) CTL
capacity of the line was confirmed by examination of cross-subtype
reactivity to rVV expressed Envelope proteins representing
subtypes A, B, C, D, CRF01_AE, F, G and H. As predicted from
the sequences there was no cross-subtype reactivity and only the
autologous MN Env was recognized. (B) The CTL assay also
confirmed that both peptide #75 and #76 pulsed TBC were lysed
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detected by an ELISPOT assay (data not shown). (C) The peptide
76 reactive T cell line could recognize the original Env peptide
pools that were use for direct ex vivo ELISPOT screening in an
ICS format assay. The predicted Env pools 3 & 4, which contain
the peptides 75–76 were recognized at a frequency of 41 and 51%
respectively by ICS. For the Becton Dickenson Env peptide pool
(containing 160 HIV-1 Env peptides) recognition was only 10.2%.
The individual peptide #76 was recognized at a frequency of
56%. vSC8; control vaccinia, us; unstimulated, PP; peptide pool.
(TIF)
Protocol S1 Trial Protocol.
(PDF)
Checklist S1 CONSORT Checklist.
(DOC)
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